Cardiovascular events and death in children exposed and unexposed to ADHD agents - Wikidata - awgldk - TriplyDB

Cardiovascular events and death in children exposed and unexposed to ADHD agents

Cardiovascular events and death in children exposed and unexposed to ADHD agents

http://www.wikidata.org/entity/Q33901929

about

ADHD drugs and serious cardiovascular events in children and young adults ADHD medications and risk of serious cardiovascular events in young and middle-aged adults.Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study Meta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults Pharmacoepidemiological safety studies in children: a systematic review Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, or conduct disorder Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents Latest trends in ADHD drug prescribing patterns in children in the UK: prevalence, incidence and persistence Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine.Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: focus on clinical efficacy and safety.Blood Pressure, Heart Rate, and CNS Stimulant Medication Use in Children with and without ADHD: Analysis of NHANES Data.Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder Attention-Deficit Hyperactivity Disorder and Long-QT Syndrome: Risky Business Long-QT Syndrome and Therapy for Attention Deficit/Hyperactivity Disorder.Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: a nationwide prospective cohort study.Methylphenidate off-label use and safety.Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review.Amphetamines, atomoxetine and the risk of serious cardiovascular events in adults.Off-label use of atomoxetine in adults: is it safe?Cardiac screening prior to stimulant treatment of ADHD: a survey of US-based pediatricians.Costs and benefits of targeted screening for causes of sudden cardiac death in children and adolescents Adverse drug reactions - examples of detection of rare events using databases.Survey of United States child and adolescent psychiatrists' cardiac screening practices prior to starting patients on stimulants Improving postapproval drug safety surveillance: getting better information sooner Sudden unexplained cardiac arrest in apparently healthy children: a single-center experience Does childhood attention-deficit/hyperactivity disorder predict risk-taking and medical illnesses in adulthood?Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder. Systematic review of review papers 2009-2011. An update for clinicians.Suicide related events and attention deficit hyperactivity disorder treatments in children and adolescents: a meta-analysis of atomoxetine and methylphenidate comparator clinical trials Sudden Cardiac Death in the Young Attention deficit hyperactivity disorder and athletes.Attention-deficit hyperactivity disorder medication use: factors involved in prescribing, safety aspects and outcomes.The use of lisdexamfetamine dimesylate for the treatment of ADHD.Attention-deficit/hyperactivity disorder, stimulant therapy, and the patient with congenital heart disease: evidence and reason.Evolution of the Study of Methylphenidate and Its Actions on the Adult Versus Juvenile Brain.Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.Comparative safety of selective serotonin reuptake inhibitors among pediatric users with respect to adverse cardiac events.Background, clinical features and treatment of attention deficit hyperactivity disorder in children.Cardiovascular safety of stimulants in children: findings from recent population-based cohort studies.Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder: an update.

P2860

Q22250876-BE16D0E1-9DB8-4DF4-9EDC-5CC20DED8D1F Q22253017-33627E9B-D5D8-4C60-A7C1-645EB42FAD25 Q24658644-8928C719-0CFD-4001-B81D-3C87AEC9D599 Q26858868-AFA6CD7C-FE64-4396-B8B8-C0739077C83E Q28077862-8FE6D635-8A66-4867-A7C0-EE2A84F1DB19 Q28260681-068F1C5E-AD30-4DBC-B673-ACC9979185EA Q28282770-C389F502-98A2-40E5-8E47-66A4CBB253C6 Q28596811-F424F0D1-7EEB-4D71-915F-A699A4EA2196 Q28729087-0728E278-D4B7-4976-8D3D-DA9F1D2EFE9D Q30399107-084A68AE-2243-4F18-A8A3-4776C1B2CA1F Q30593927-6A8EF76A-C461-47BC-A60D-9CA137EC9165 Q30857557-1D6E589B-F503-40AC-8111-4F9162A784B7 Q33160890-0E02B2B9-3A9D-4741-B325-6D47D6A28C17 Q33165891-E57B9033-8474-4961-B94C-378A09AD3DB1 Q33165982-425C6D0E-97D1-40C0-8A93-579259962C9B Q34063584-9BBFEA0A-ED93-4989-9456-CE5F9A782F35 Q34172165-FE66BADD-CB6A-4C61-B33B-085510CE5C73 Q34280107-92A495F3-C797-4198-AB18-DDA32FA85A10 Q34575150-A8BC9B04-5C49-40D4-BA5C-D1A93EB2C52C Q34618993-5E9ED4DF-D792-4566-8AC4-475D9360C203 Q35715230-4B94F17B-4967-45BB-BB6E-70DB7017D651 Q36002613-6479F9F6-6707-4112-9253-CA3C7CFC7C64 Q36125541-31C18327-5977-449B-91C5-0E7066A2ACFC Q36351008-D6BFB723-506B-4021-978D-980E6392C9AB Q36367834-5180ED58-5317-400E-B633-39D9BEF0F495 Q36592584-CCDD3C4B-B2C9-4D4D-94DB-C546D990C11A Q36871524-3341F66A-6E5A-4308-A88E-7831CAF9514D Q36873921-3114C2F9-28C4-4C77-8186-329069D9E71E Q36952424-38B87218-F8CE-458C-8901-3EF9B822C21B Q37275861-2D42215D-5EAE-477D-98B5-11D598354878 Q37596910-63378A94-8A81-4D30-8D4F-A5AF172100D3 Q37722786-3E021ED1-0E15-4865-AAE0-650A6B62CE29 Q37975550-E0FF6F2C-0A36-495B-B9D4-FADBA535172D Q37980690-E89A3A9C-0526-4359-831D-7B06083E2E47 Q38038163-DDAC6D7F-224C-40DC-B1C8-DEEB8F1770AF Q38060572-B1F1CCD2-E892-4865-B225-BED9928AC4D6 Q38086176-5ABA8A90-BE26-4C6A-B0B8-76A0F4290BAD Q38122410-709CC16D-3327-4DC2-A0CB-631C772577E4 Q38126419-0D0344C8-E19E-4737-9F59-0A7636DBDEA8 Q38240014-0B388FED-C646-4BD8-8ACD-9D15DC64394B

P2860

Cardiovascular events and death in children exposed and unexposed to ADHD agents

http://www.wikidata.org/entity/Q33901929

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Cardiovascular events and death in children exposed and unexposed to ADHD agents

@ast

Cardiovascular events and death in children exposed and unexposed to ADHD agents

@en

type

label

Cardiovascular events and death in children exposed and unexposed to ADHD agents

@ast

Cardiovascular events and death in children exposed and unexposed to ADHD agents

@en

prefLabel

Cardiovascular events and death in children exposed and unexposed to ADHD agents

@ast

Cardiovascular events and death in children exposed and unexposed to ADHD agents

@en

P1433

Q33901929-070BF0F1-6645-4240-BCFB-9CC0CC7C4BE9

P1476

Q33901929-023DE9BB-64FB-480C-8BD2-87AC2800A9ED

P2093

Q33901929-1C039C58-56BA-4349-B7B5-761639910BB1

Q33901929-5B922154-1A0C-4FBE-81CB-177862A604F8

Q33901929-63B36B70-FD15-41AC-84E4-B57D683F8D1E

Q33901929-76ABAA06-95B0-4EFF-BF9B-C0744B8C7365

Q33901929-9555720B-FB22-4D32-A88F-B5A98D1A6233

Q33901929-986E72B1-3F55-4106-9D55-49E900A1C936

Q33901929-D5C87A5C-B7AC-4E7B-A56E-7DAF613815E5

Q33901929-F0D71637-1AA1-4C9A-ACE7-A82B2C34635A

Q33901929-F70DB675-DAA8-4076-AC61-2E72E6E8C231

P2860

Q33901929-09E5D0D3-924A-4DB8-8D72-1C104F8AC60C

Q33901929-22B17994-F5E1-4307-9C14-FFB2FE17C751

Q33901929-248A6028-533D-47F4-8013-EA285FBDCE10

Q33901929-255ADD86-D77D-44CD-8481-E62B29F0879F

Q33901929-47EC49DC-DA92-4C8A-9E31-7E80F0495578

Q33901929-4C222348-2947-4B2C-8EA5-927B5F47BBC6

Q33901929-4E9289FD-307C-4738-A991-EB87B77437C6

Q33901929-5413F20E-B4AD-4D67-8AA2-5F76ABA34FEF

Q33901929-5E7D8712-3ECF-4321-BF3D-0484C1811E64

Q33901929-6654A4F4-B820-4AD4-889E-B1F6F0984EA8

P304

Q33901929-A8A60FFE-307C-409C-AC6A-A76D9B58EBC2

P31

Q33901929-1B6CC94A-5AF4-4C92-B7B9-D9F729CC12D5

P356

Q33901929-A2BAEB87-29F2-43CE-920E-B4D5AC0A3004

P407

Q33901929-A21152F2-E923-432A-9BCB-A0A710C4B01E

P433

Q33901929-4CDE6D74-659F-4E11-B85B-E587F766378C

P478

Q33901929-4ED8C2C0-6C0E-4565-8651-B68B67EA26B7

P577

Q33901929-C735BCC6-0E61-4B8A-B1D6-AD977EA181E3

P5875

Q33901929-5B225E19-7077-44AF-8D8B-A06940E7318E

P698

Q33901929-C943A9F1-A8FE-4F95-AB61-0E2631AAD70F

P921

Q33901929-64EBB0DF-58F0-4273-8EA6-52E6D98F20D8

P932

Q33901929-A652B5CB-6717-4BBF-B0B6-D298CDD02C14

P356

P1433

P1476

Cardiovascular events and death in children exposed and unexposed to ADHD agents

@en

P2093

Brian L Strom

http://www.w3.org/2001/XMLSchema#string

Craig Newcomb

http://www.w3.org/2001/XMLSchema#string

Gregory W Daniel

http://www.w3.org/2001/XMLSchema#string

Hedi Schelleman

http://www.w3.org/2001/XMLSchema#string

James P Guevara

http://www.w3.org/2001/XMLSchema#string

Mark J Cziraky

http://www.w3.org/2001/XMLSchema#string

Sean Hennessy

http://www.w3.org/2001/XMLSchema#string

Stephen E Kimmel

http://www.w3.org/2001/XMLSchema#string

Warren B Bilker

http://www.w3.org/2001/XMLSchema#string

P2860

ADHD drugs and cardiovascular risk

Marginal structural models and causal inference in epidemiology

Validation of diagnostic codes for outpatient-originating sudden cardiac death and ventricular arrhythmia in Medicaid and Medicare claims data.

Cardiovascular safety of ADHD medications: rationale for and design of an investigator-initiated observational study.

Incidence and occurrence of total (first-ever and recurrent) stroke.

Temporal changes in the outcomes of acute myocardial infarction in Ontario, 1992-1996

Positive predictive value of the diagnosis of acute myocardial infarction in an administrative database.

Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records.

Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the Women's Health Initiative.

The Greater Cincinnati/Northern Kentucky Stroke Study: preliminary first-ever and total incidence rates of stroke among blacks.

P304

1102-1110

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1542/PEDS.2010-3371

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

127

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51130648

http://www.w3.org/2001/XMLSchema#string

P698

21576311

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

P932

3387871

http://www.w3.org/2001/XMLSchema#string